Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

Keyphrases

• Acute Effects 10%
• Acylate 60%
• Acylated Peptides 10%
• Agonism 100%
• Antagonism 100%
• Blood Glucose 10%
• Body Weight Changes 10%
• Cell Systems 10%
• Chronic Treatment 20%
• Co-treatment 20%
• Cross-reactivity 10%
• Cross-species Activity 10%
• DIO Mice 80%
• Dose Effect 10%
• Duration of Action 20%
• Energy Expenditure 10%
• Extended Duration 10%
• Fatty 20%
• Feeding Experiment 20%
• Food Intake 20%
• Functional Assay 10%
• GIP Receptor 100%
• GIP Receptor Agonist 30%
• GIP Receptor Antagonist 30%
• GLP-1 Receptor Agonist 20%
• Glucagon Receptor 10%
• Glucagon-like peptide-1 Receptor (GLP-1R) 40%
• Glucose Tolerance 10%
• Glycemic Control 10%
• High Dose 10%
• In Vitro Antagonism 10%
• In Vivo Efficacy 20%
• Increased Body Weight 10%
• Indirect Calorimetry 20%
• Liraglutide 20%
• Low Body Weight 20%
• Obese Mice 10%
• Overexpressing 10%
• Pair-feeding 20%
• Peptide-based 30%
• Pharmacology 20%
• Reactive Activity 10%
• Receptor Selectivity 10%
• Rodents 10%
• Weight Loss 10%
• Weight Reduction 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Calorimetry 9%
• Diet Induced Obesity 36%
• Gastric Inhibitory Polypeptide 100%
• Glucagon Receptor 4%
• Liraglutide 9%
• Mouse Mutant 4%
• Receptor 100%
• Receptor Agonist 13%
• Receptor Antagonist 13%